Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
McAteer A, Yi D, Watson V, Norwood P, Ryan M, Hannaford PC, Elliott AM. Exploring preferences for symptom management in primary care: a discrete choice experiment using a questionnaire survey. Br J Gen Pract. 2015 Jul;65(636):e478-88. doi: 10.3399/bjgp15X685705
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Whalley D, Gravelle H, Sibbald B. Effect of the new contract on GPs' working lives and perceptions of quality of care: a longitudinal survey. Br J Gen Pract. 2008 Jan 1;58(546):8-14.
Whalley D, Bojke C, Gravelle H, Sibbald GP. GP job satisfaction in view of contract reform: a national survey. Br J Gen Pract. 2006 Feb 1;56(523):87-92.
Ryan M, Watson V. Editorial - Counting the cost of fast access: using discrete choice experiments to elicit preferences in general practice. Br J Gen Pract. 2006 Jan;56(522):4-5.